David Thompson

Corporate Officer/Principal en INOZYME PHARMA, INC. .

Consumer Services

Health Technology

Perfil

David Thompson is the founder of Azure Biotech, Inc. He is currently a Member-Scientific Advisory Board & Senior Advisor at Inozyme Pharma, Inc. His former position at Inozyme Pharma, Inc. was Chief Scientific Officer & Senior Vice President from 2018 to 2020.
Dr. Thompson has a graduate and doctorate degree from the University of Connecticut and a graduate degree from The University of Montana.

Cargos activos de David Thompson

Empresas	Cargo	Inicio
INOZYME PHARMA, INC.	Corporate Officer/Principal	01/07/2021

Todos los cargos activos de David Thompson

Antiguos cargos conocidos de David Thompson.

Empresas	Cargo	Fin
INOZYME PHARMA, INC.	Chief Tech/Sci/R&D Officer	13/10/2020
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Founder	-

Ver el detalle de la experiencia de David Thompson.

Formación de David Thompson.

University of Connecticut	Doctorate Degree
The University of Montana	Graduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de David Thompson.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	1
INOZYME PHARMA, INC.	Health Technology

Empresas privadas	1
Azure Biotech, Inc. Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson.	Health Technology